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Background: Estrogens play an important role in breast cancer (BC) development and progression; when the two
isoforms of the estrogen receptor (ERα and ERβ) are co-expressed each of them mediate specific effects of these
hormones in BC cells. ERβ has been suggested to exert an antagonist role toward the oncogenic activities of ERα,
and for this reason it is considered an oncosuppressor. As clinical evidence regarding a prognostic role for this
receptor subtype in hormone-responsive BC is still limited and conflicting, more knowledge is required on the
biological functions of ERβ in cancer cells. We have previously described the ERβ and ERα interactomes from
BC cells, identifying specific and distinct patterns of protein interactions for the two receptors. In particular, we
identified factors involved in mRNA splicing and maturation as important components of both ERα and ERβ pathways.
Guided by these findings, here we performed RNA sequencing to investigate in depth the differences in the early
transcriptional events and RNA splicing patterns induced by estradiol in cells expressing ERα alone or ERα and ERβ.
Results: Exon skipping was the most abundant splicing event in the post-transcriptional regulation by estradiol. We
identified several splicing events induced by ERα alone and by ERα + ERβ, demonstrating for the first time that ERβ
significantly affects estrogen-induced splicing in BC cells, as revealed by modification of a subset of ERα-dependent
splicing by ERβ, as well as by the presence of splicing isoforms only in ERβ + cells. In particular, we observed that
ERβ + BC cell lines exhibited around 2-fold more splicing events than the ERβ- cells. Interestingly, we identified putative
direct targets of ERβ-mediated alternative splicing by correlating the genomic locations of ERβ and ERα binding sites
with estradiol-induced differential splicing in the corresponding genes.
Conclusions: Taken together, these results demonstrate that ERβ significantly affects estrogen-induced early
transcription and mRNA splicing in hormone-responsive BC cells, providing novel information on the biological role of
ERβ in these tumors.
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Breast cancer (BC) is the most frequent cancer in women
worldwide [1], and its development and progression are
known to rely strongly on the stimulation by female sexual
hormones, especially estrogens. Estrogen receptors α (ERα)
and β (ERβ) are transcription factors that mediate the
actions of estrogens in target cells [2,3]. Ligand binding to* Correspondence: aweisz@unisa.it
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unless otherwise stated.ERα or ERβ induces receptor dimerization, either as homo-
dimers (ERα/ERα or ERβ/ERβ) or heterodimers (ERα/ERβ)
[4], and promotes its translocation to the nucleus and
binding of target chromatin sites via Estrogen Response
Elements (EREs) and other regulatory elements on DNA
[5]. Although encoded by different genes, ERα and ERβ
share the same general modular protein structure of the
nuclear hormone receptor superfamily, and have almost
100% amino acid sequence homology in their DNA-
binding domain. They also show 59% amino acid hom-
ology in their ligand-binding domains [4,5]. The two
ERs are thus quite similar in sequence and structure,
but ERβ has considerably different and, in most cases,
opposite biological effects compared to ERα in BC cells,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of hundreds of genes [6], enhancing BC cell growth,
proliferation and survival in response to estrogens [7].
The specific role of ERβ and its impact in BC are un-
clear. This ER subtype is expressed in 70% of human
breast tumors in combination with ERα, even if some
human breast tumors express only ERβ [8-10]. Several
reports have suggested that ERβ has anti-proliferative
action in BC cells, by increasing the expression of anti-
proliferative genes and/or decreasing the expression of
proliferative and anti-apoptotic genes [11-15] and the
ERα/ERβ ratio determines the cell-specific response to
estrogen. In BC this ratio is higher than in normal tis-
sues, due to up-regulation of ERα and down-regulation
of ERβ [16]. Loss of ERβ mRNA levels in cancer can
occur as a result of promoter methylation [17]. These
observations have suggested a positive prognostic value
of this receptor subtype [12,18]. However, several studies
have reported also a negative prognostic value for ERβ
expression [19,20], making the overall contribution of this
receptor isoform to BC biology unclear.
The exact mechanism of the antagonism between ERβ
and ERα is only partially known. As the two receptors
share only 30% homology in their transactivation do-
main AF1 [5], it is likely that they show different pat-
terns of interaction with coregulatory proteins. Indeed,
we have previously reported that the protein interac-
tomes of both ERβ and ERα show significant differences
of the protein complexes engaged by the two ER sub-
types [21-25]. A particularly interesting subset of inter-
acting proteins, with only partially overlapping interaction
patterns between the two receptors [26], comprises factors
involved in RNA maturation and splicing [Additional
file 1: Figure S1] [26].
Alternative splicing is a mechanism by which cells can
increase the variability of their proteomes by changing
the composition of transcribed genes through differential
choice of exons to be included in the final mRNA mol-
ecule [27]. Almost 90% of human genes show alternative
splicing during development, cell differentiation and
disease [28]. Recent studies have shown the existence
of cancer-specific splicing events by which transformed
cells switch from the adult isoform of the gene to a
more embryonic one, contributing to the cancer pheno-
type [29-31].
Alternative splicing events have been monitored in BC
and in numerous tumor types [32], and ERα itself has
been reported to induce alternative splicing of a spe-
cific set of genes [33-35]. Here, we investigated the
ability of ERβ to regulate mRNA maturation and spli-
cing in hormone-responsive BC cells. To this purpose,
we performed high-throughput RNA sequencing (RNA-
seq) analysis of human MCF-7 cell lines stably trans-
fected with ERβ, and compared them with the wild typeline, expressing only ERα, upon 17β-estradiol (E2)
stimulation.
Results
High-throughput sequencing in ERβ + and ERβ- human BC
cell lines
We have previously established and characterized sub-
clones of the human BC cell line MCF-7 expressing hu-
man ERβ fused to a Tandem Affinity Purification (TAP)
tag, and have shown that the addition of the TAP-tag at
either the N- or the C-terminus of the protein (indicated
as Nt-ERβ and Ct-ERβ, respectively) does not alter sig-
nificantly the receptor function, nor its ability to activate
transcription or to antagonize ERα-dependent transcrip-
tion [21,22,36]. In order to study the early events of
hormone-induced pre-mRNA maturation, we used these
stable cell lines to perform deep-sequencing analysis of
estrogen-induced transcriptional events shortly after
stimulation with 17β-estradiol (2 h), to focus mostly on
primary transcriptional events [21,36]. For comparison,
we also performed the experiment in wild-type MCF-7
cells, which do not express endogenous ERβ.
Almost 70 million reads/replicate were aligned against
the reference human genome for ERβ- and ERβ + BC
cell lines. The number of reads for genes and isoforms
were normalized to “Fragment Per Kilobases of exon per
Million of mapped reads” (FPKM). In order to analyze
genes and isoforms, we set 0.5 FPKM (at least one ana-
lyzed condition, with/without E2 stimulus) as the expres-
sion level threshold. In this way, we identified 16,821
(MCF-7 wt), 16,148 (Ct-ERβ) and 17,135 (Nt-ERβ) genes
as expressed. The criteria for considering genes and iso-
forms as significantly regulated by estradiol were: FPKM
value ≥0.5 in at least one analyzed condition, q-value
(FDR-adjusted p-value of the test statistics) ≤0.05 and
|fold-change| (FC) ≥1.3 [Additional file 2: Table S1].
As shown in Figure 1, 895 (MCF-7 wt), 2,899 (Ct-ERβ)
and 3,043 (Nt-ERβ) genes were detected as significantly
regulated by E2 in these BC cell lines. Expression of
ERβ in MCF7 cells significantly affected the estrogen-
dependent gene expression profile: the regulation of
around 230 genes (≈25% of E2-regulated genes) was
lost in both cell lines expressing ERβ, while a large
number of genes which were not regulated in wt cells
became significantly regulated in Ct-ERβ (2,396) and
Nt-ERβ (2,463) clones (Figure 1). The genes regulated
consistently in both ERβ + lines are reported in Additional
file 2: Tables S1-D. Interestingly, expression of ERβ in this
BC cell line had a stronger effect on inhibited genes than
on the activated ones: regulation of 40% of genes inhibited
by estradiol in wt cells was lost in both ERβ + cell lines,
versus 14% for estrogen-activated genes. Gene Ontology
analysis revealed that among the most enriched functions
in the group of genes whose regulation by estradiol was
Figure 1 Venn diagram of expressed genes in ERβ + and wt breast
cancer cell lines. The Venn diagram shows the number of genes
regulated by estradiol in the three cell lines, as indicated: wt (parental
MCF-7 cells); Ct-ERβ (MCF-7 subclone stably expressing ERβ tagged
with the TAP-tag at the C-terminus); Nt-ERβ (MCF-7 subclone stably
expressing ERβ tagged with the TAP-tag at the N-terminus). The pie
charts in the lower panels specify the direction of regulation by
estradiol (induction or repression) of the genes whose regulation is
present in wt cells but is lost in both ERβ + cell lines (left panel), or of
the genes whose regulation by estradiol is not present in the wt cells
but appears in both ERβ + lines (right panel).
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Replication, Recombination and Repair, as well as Cell
Cycle and Cell Morphology (data not shown).
Estrogen-dependent splicing events in ERβ + and ERβ-
human BC cell lines
Events of exon skipping, mutually exclusive exons, alterna-
tive start, stop splice site and intron retention were anno-
tated using the Multivariate Analysis of Transcript Splicing
(MATS) software [37] [Additional file 3: Tables S2]. Exon
skipping appeared to be the predominant splice event in all
cell lines analyzed. MATS reveled in detail 1,264 (Ct-ERβ),
1,402 (Nt-ERβ) and 975 (MCF-7 wt) exon skipping events
induced by estradiol, associated with 1,016 (Ct-ERβ), 1,117
(Nt-ERβ) and 816 (wt MCF-7) genes (Figure 2A). Five
hundred seventy-five events were common to all the cell
lines analyzed while 115 showed opposite exon inclusion
level in ERβ + lines compared to ERβ- wt cells. We also
observed high levels of retained intron and mutually ex-
clusive exons events, confirming a complex and significant
effect of ERs on the regulation of RNA splicing in these
cell lines (Figure 2A).
To focus on the differences in splicing patterns between
ERβ + and ERβ- cell lines, we first looked at the geneswhich were regulated by estradiol in opposite direction in
ERβ + cells versus wt cells [Additional file 4: Table S3].
Among 298 regulated genes, 56 also underwent estradiol-
induced alternative splicing in at least one of the cell lines,
confirming that pre-mRNA maturation was regulated
concurrently with transcription in a significant fraction
of ERβ-regulated genes (Figure 2B). These ERβ-regulated
genes undergoing alternative splicing included transcrip-
tional regulators (NCOR2, ZNF189, MLXIP, ANKRD12,
HSF1), enzymes involved in nucleoside/nucleotide metab-
olism (GUK1, NME3, NME4), actin remodeling and cellu-
lar transport processes (TNS3, TRAPPC6A, TMSB15B,
KIF12), and protein translation (ZNF98, EEF1D, RPL10,
RPL18, RPS18).
Estrogen-induced differential splicing has been repor-
ted also in genes independently on transcriptional regula-
tion [35]. In order to find the splicing events differentially
regulated by estradiol in ERβ + compared to wt cells, we
scanned the whole list of expressed genes for splicing pat-
terns occurring differentially in ERβ + vs ERβ- cells. In
addition, we focused on those splicing events whose oc-
currence significantly altered the ratio between different
isoforms of the same gene. Therefore, for each isoform we
calculated the percentage of gene expression associated
with that particular isoform (FPKM ratio: FPKMisoform/
FPKMgene %) and selected for further analysis only those
isoforms in which estradiol induced a change in FPKM
ratio of at least 10% either in wt MCF-7 or in both ERβ +
cell lines. Other criteria of inclusion were: occurrence
of at least one splicing event as detected by MATS;
at least one isoform of the gene with FPKM value ≥0.5 in
at least one analyzed condition, q-value ≤0.05 either in wt
or in both ERβ + cell lines; regulation in both ERβ + lines
in opposite directions compared to the wt. In this
way, we identified the quantitatively most relevant
splicing events differentially regulated by E2 in ERβ +
versus ERβ- cells, including 35 genes whose isoform
composition changed significantly after E2 stimulation
in an ERβ-dependent fashion (Figure 3). Among these, we
found genes involved in apoptosis (BAD), lipid metabol-
ism (ACADM, PLSCR1, SLC27A2, STARD4), nutrient
transport (SLC25A19, SLC35C2), transmembrane receptor
signaling (IFNGR2, LDLRAD4), Notch signaling (PSEN2,
POGLUT1, SGK1, SLC35C2), as well as some non-coding
RNAs (MCM3AP-AS1, SNHG17). An example of a gene
whose splicing pattern was affected by estradiol in an ERβ-
dependent fashion is reported in Figure 4A, showing the
gene SGK1, which encodes a serum and glucocorticoid-
induced serine/threonine protein kinase involved in ion
transport affecting many cellular processes such as cell
growth, proliferation, survival, apoptosis and migration
[38,39]. The gene was induced by estradiol in both wt and
ERβ + cells; however, expression of ERβ in the absence of
hormonal stimulation induced a promoter usage switch
Figure 2 (See legend on next page.)
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Figure 2 Annotation of splice events in ERα + and ERα + ERβ + BC cell lines. (A) The bar plot shows the number of all alternative splicing events
occurring in the cell lines analyzed. Inclusion and exclusion behavior for each event are shown (FDR≤ 0.05; c≤ |0.1|). (B) Genes whose regulation
has opposite direction in the ERβ + lines compared to the wt MCF-7. The heat map on the right side shows the gene expression fold changes
induced by estradiol. The matrix on the left side shows in black those genes for which a splicing event was detected in at least one of the cell
lines. The nomenclature for the cell lines is the following: wt (parental MCF-7 cells); Ct-ERβ (MCF-7 subclone stably expressing ERβ tagged with
the TAP-tag at the C-terminus); Nt-ERβ (MCF-7 subclone stably expressing ERβ tagged with the TAP-tag at the N-terminus).
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tive translation start site and therefore the expression
of an isoform with a different N-terminal sequence
(ENST00000367857), compared to the major isoform
expressed (ENST00000237305). It has been reported
that alternative isoforms at the N-terminus can affect
SGK1 localization and protein stability: the ERβ-specific
form with intron-retention misses a very crucial sequence
involved in targeting to the endoplasmic reticulum as well
as in proteasomal degradation [40].
This data suggests that expression of ERβ causes switches
in estradiol-induced splicing patterns, potentially affecting
expression or function or ER targets.
Estrogen-dependent alternative promoter usage in ERβ + vs
ERβ- BC cells
As the usage of alternative promoters is a major deter-
minant of protein diversity, even more than alternative
splicing [41,42], we next focused on utilization of mul-
tiple promoters. We grouped the primary transcripts of
a gene based on the promoter used, and subsequently
tested changes in primary transcript abundance by
measuring the square root of the Jensen-Shannon diver-
gence that occurred within and between the analyzed
groups. Finally, we investigated the potential promoter
switch regulation for the genes comprising more than
one differentially expressed transcript initiating from
distinct genomic loci. There were 977 (Ct-ERβ), 402
(Nt-ERβ) and 222 (wtMCF-7) distinct promoter-switching
genes (FDR ≤ 0.05) in ERβ + and ERβ- BC cell lines, re-
spectively [Additional file 5: Tables S4A-C]. Of the 222
promoter-switching genes recorded in wt MCF-7 cells,
165 did not show promoter switch in both ERβ + cell lines,
while 61 new promoter-switching events, not present in
wt cells, were detected in both ERβ + lines. These 61 ERβ-
specific promoter-switching genes are involved in import-
ant cellular functions known to be controlled by E2 in BC
cells, such as transcription (FOXJ3, GTF2H, NR2C2AP),
DNA metabolism and repair (PRKDC, REV3L, SCAND3),
pre-mRNA maturation and splicing (PPM1G, PRPF38B,
RNMT, RPRD1A, SMG1), translation (FARSB, RARS,
RPS21, UTP20), protein ubiquitination and proteasome
pathway (CUL5, KLHL2, PSMB1, USP7), cytoskeleton and
cytokinesis (DCTN4, MYL12A, SEPT9, SYDE2), mem-
brane metabolism, remodeling and intracellular transport
(ATP9A, CAST, MAL2, PSD3, TMEM43, TRAPPC9), celladhesion and polarity (ARHGAP12, CD9, CLDN7,
EPB41L5, PERP), signal transduction (MAP3K5, NGFRAP1,
TNFRSF12A,WWC3, ZDHHC5).
As an example, we focused on the PSD3 gene, predicted
to be a nucleotide exchange factor for ADP Ribosylation
Factor (ARF) 6, a member of the RAS family involved in
vesicular trafficking, remodeling of membrane lipids, and
signal transduction [43]. As show in Figure 4B, for this
gene we found 9 distinct primary transcripts (TSS01-
TSS09) whose usage ratios changed with E2 stimulus
(right panel) compared to the control untreated cells
(left panel). In ERβ + cells, estradiol induced a switch
from promoter TSS08 (ENST00000523619) to the down-
stream promoter TSS02, resulting in a shorter transcript
(ENST00000519653), which is predicted to undergo
nonsense-mediated decay [Additional file 6: Table S5].
Estrogen-dependent splice ratios in ERβ + vs ERβ- cells
To obtain a comprehensive view of the estrogen-induced
differences in the splice ratios between wt, Ct-ERβ and
Nt-ERβ cells, we employed Cuffdiff v2.1.1 [44], which
calculates the changes in splice isoforms abundance, by
quantifying the square root of the Jensen-Shannon diver-
gence, considering each primary transcripts able to pro-
duce multiple isoforms. We determined 217 (Ct-ERβ),
241 (Nt-ERβ) and 95 (MCF-7 wt) differentially spliced
genes (DSGs, i.e. genes for which estradiol challenge
induced at least one splicing event) with a FDR
value <0.05 [Additional file 5: Tables S4D-F]. Of the
95 spliced genes detected in wt cells, sixty-nine lacked
splicing events in both ERβ + cell lines, suggesting inhib-
ition of ERα-dependent splicing by ERβ. Moreover, 28
ERβ-specific DSGs, in which no estrogen-induced splicing
was recorded in wt cells, were found in both ERβ + cell
lines. These include genes involved in mitosis and cyto-
kinesis (SEPT9, BICD2, ENSA, PDS5A), cell cycle control
(CCNJ, RAN), transcription (C11orf30, EIF3M, HIPK1,
PBX1, ZNF124, ZNF131), protein folding (DNAJB6,
HSP90B1), ubiquitination and sumoylation (DCUN1D4,
SENP5,TRIM33), and signal transduction (APBB2, RTKN2).
Correlation between ER binding and ER-dependent splicing
In order to identify direct splicing targets of ERα and ERβ,
we next investigated the presence of ERα and ERβ binding
sites in genomic locations close to the identified DSGs
[Additional file 7: Table S6]. To verify the specificity of ER
Figure 3 Selected isoform switches affected by the expression of
ERβ. The ERβ-dependent differential splicing events that affect most
prominently the balance of different isoforms for each gene were
identified by using the following parameters: (i) isoform ratio
(FPKMisoform/FPKMgene %) changing of at least 10% after estradiol
stimulation, either in the wt cells or in both the ERβ + cells in at least
one of the isoforms of the gene; (ii) at least one isoform of the gene
significantly regulated by estradiol (p-value≤ 0.05; |FC|≥ 1.3) either in
the wt cells or in both the ERβ + cells; (iii) isoform ratio changing in
opposite direction in the wt cells compared to the ERβ + cells; (iv) at
least one splicing event identified by MATS analysis. Thirty-five genes
satisfied all the selection requirements; of these, only 2 to 3 isoforms
were selected for presentation, according to the expression levels and
the regulation by estradiol. Left panel: heat map of regulation of the
selected genes by estradiol in: Ct-ERβ (MCF-7 subclone stably expressing
ERβ tagged with the TAP-tag at the C-terminus); Nt-ERβ (MCF-7
subclone stably expressing ERβ tagged with the TAP-tag at the
N-terminus); wt (parental MCF-7 cells). Right panel: heat map with the
change in isoform ratio (FPKMisoform/FPKMgene %) between E2-treated
and non-treated cells in the indicated cell lines; for each gene, at least
two different isoforms are presented, to show estrogen-induced switch
from one isoform to the other.
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published ChIP-Seq data [21,45]. The binding densities of
ERα and ERβ were clustered according to the seqMINER
platform [46]. In the clustering shown in [Additional file
8: Figure S2], each line represents a genomic location of a
binding site with its surrounding ±1.5 kb region. In the left
panel, ERα binding sites were used as a reference to col-
lect a ChIP-seq tag densities window in ERβ + and ERβ-
cell lines, while in the right panel ERβ binding sites were
used as a reference. The heat map, representing the clus-
tered density matrix, confirmed that ERβ presence modi-
fied a significant number of ERα binding sites. In order to
investigate the correlation between ERα and ERβ DNA
binding and splicing events, we compared our RNA-Seq
data with the ChIP-Seq data we had previously obtained
in these same cell lines [21]. We considered the binding
sites included within regions spanning 10 kb upstream or
downstream of all DSGs in each cell line. The Circos plot
[47] in Figure 5 shows the DSGs for which estradiol chal-
lenge induced at least one splicing event in both ERβ + cell
lines with a nearby binding site for ERα and/or ERβ. The
outer ring (blue) reports the ERα binding sites, while the
inner ring (red) shows the ERβ binding sites. Based on
ERα and ERβ binding, we distinguished three different
DSGs groups. Group 1 DSGs were associated with both
ERα and ERβ binding sites (black). Group 2 includes
DSGs associated with ERα binding sites exclusively (blue)
and group 3 DSGs associated with ERβ binding sites ex-
clusively (red). The vast majority of genes exhibited both
binding sites (Group 1), confirming the competing role of
ERα and ERβ. Interestingly, among the putative direct
ERβ splicing targets we found many genes involved in
transcription: transcription factors (FOXN3, NFIB, TAF6,
TCF12, ZNF295, ZNF438), histone methyltransferases
Figure 4 Examples of ERβ-specific splicing events. A) Example of alternative splicing in the SGK1 gene. The upper panel shows a schematic
representation of two differentially regulated isoforms of the gene (same as those shown in Figure 3 for the same gene), differing in the transcription
start site, in the inclusion of the first intron (the gene is encoded by the reverse strand) and in the transcription stop site. The lower panels show a
representation of the RNA-Seq reads and junction reads associated with the gene in the different conditions: Ct-ERβ (MCF-7 subclone stably expressing
ERβ tagged with the TAP-tag at the C-terminus) without or with E2 stimulation, and wt (parental MCF-7 line) without or with E2 stimulation. B) Example of
ERβ-specific alternative promoter usage in the gene PSD3. The left panel shows a heat map with the fold change of all the primary transcripts associated
with the gene in: Ct-ERβ (MCF-7 subclone stably expressing ERβ tagged with the TAP-tag at the C-terminus); Nt-ERβ (MCF-7 subclone stably expressing
ERβ tagged with the TAP-tag at the N-terminus); wt (parental MCF-7 cells). The right panels show the logarithm base 10 (log10) FPKM for each of the
different transcript start sites (from TSS01 to TSS09) corresponding with the different gene isoforms in the above described cell lines, without (left) or
with (right) E2 stimulation.
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Figure 5 Correlation between ERβ-specific splicing and ER binding. Circos plot of differential spliced genes (DSGs) common to both ERβ + cell
lines which contain at least one ER binding event within a window of 10 kB around the gene. The outer ring shows chromosome ideograms with
the relative genes located in their respective chromosomal locations, with the following color code: the genes that have both ERβ and ERα binding
are in black; the genes which have only ERβ binding are in red; the genes which have only ERα binding are in blue. The two internal rings represent
ERα and ERβ binding events in blue and red, respectively.
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(YEATS2), other transcriptional regulators (AKNA, BANP,
CHD3,MEIS2). Other interesting functions associated with
these genes are: apoptosis (BCL2L13, CASP8, C1orf201),
autophagy (AMBRA1, ATG12, ATG13, ATG16L2), splicing
(HNRNPH3, MBL2), protein ubiquitination (CNOT4,
FBXW11, RFWD2, WDR20) cytoskeleton and cytokin-
esis (AURKA, EPS8L2, EPB41L2, LARP4, NPHP4, PLEC,TLN2), primary cilium biogenesis [48] (BBIP1, IFT140,
KIAA0586), intracellular trafficking/membrane traf-
ficking (ASAP1, KIF13A, MCOLN1, RAB17, TBC1D1,
VPS29), cell adhesion (ARMC8, CD151, ELMOD3, LLP,
VMP1).
Taken together, these analyses suggest the strong effect
of ERs binding on alternative splicing and confirming
the key role of ERβ in BC cells.
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In this study we investigated for the first time the effects
of ERβ expression on estrogen-dependent pre-mRNA
maturation and splicing. We used two different subclones
of ERα-positive and estrogen-dependent MCF-7 cells sta-
bly expressing ERβ, and we found that expression of ERβ
in these cells significantly affected the estradiol-dependent
early transcriptional program and splicing pattern. In par-
ticular, introduction of ERβ caused loss of regulation of
25% of the estrogen-regulated genes. Moreover, a com-
parison between the ERβ + and the wt ERβ- cells showed
that expression of ERβ caused loss of ERα-induced pro-
moter switching in 75% of the genes, and of ERα-induced
splicing in 72% of the genes.
Besides affecting ERα-dependent transcription and
splicing, expression of ERβ caused the appearance of
ERβ-specific estrogen-responsive transcription (550 genes)
[Additional file 2: Tables S1-D], promoter-switching (61
genes) and differential splicing (28 genes) events, counting
only the events that were present in both ERβ + lines. The
biological functions of the ERβ-specific genes included
DNA replication and repair, cell cycle, apoptosis and au-
tophagy, DNA transcription, lipid metabolism, membrane
metabolism, intracellular trafficking, mRNA maturation
and translation, protein ubiquitination and sumoylation,
cell signaling, confirming that a wide variety of cellular
processes are affected by ERβ.
Based on our data, there are at least three different
mechanisms by which ERβ can affect ERα-dependent
transcription: (1) competition with ERα for binding to
target gene promoters, in the form of competitive bind-
ing or heterodimerization, which can alter the recruit-
ment of coregulators: the comparison between Chip-seq
and RNA-seq data showed that the majority of the pri-
mary targets identified in this experiment were directly
targeted by both ERα and ERβ (Figure S1), as expected
also from data in the literature [49]; (2) gain of new
binding sites that are not bound by ERα alone: a subset
of binding sites appeared in the ERβ + cells but were not
present in wt cells, again consistently with a previous re-
port comparing ERα and ERβ genomic binding patterns
in MCF-7 cells [49]; (3) secondary effects: expression of
ERβ induced transcription and splicing of transcriptional
regulators (most interestingly, the corepressor NCOR2,
involved in gene repression by tamoxifen-bound estro-
gen receptor and by unliganded NRs such as the retinoic
acid receptors) and of splicing factors, which can in turn
affect estrogen-induced transcription and pre-mRNA
maturation. For instance, ERβ induced promoter switch-
ing in the PPM1G gene, encoding a protein phosphatase
responsible for dephosphorylation of pre-mRNA splicing
factors [50]; the ERβ-specific alternate protein isoform
from this gene (ENST00000350803) has an additional 17
amino acids in the N-terminal catalytic domain comparedto the main isoform (ENST00000544412), which are likely
to modulate the enzymatic function.
Even if the sole detection of splicing events does not
give information on the biological consequences of ERβ
effects on RNA splicing, it is tempting to speculate on
the possible implications of ERβ-dependent splicing
events on BC cells. Changes in splicing patterns can
affect biological processes by many different mechanisms,
including gain-of-function or functional switches, altered
cellular localization, dominant negative effect, changes in
protein/mRNA stability. For instance, expression of ERβ
induced a promoter switch in the USP7 gene, resulting in
a shorter transcript (ENST00000535863) compared to the
major isoform expressed in wt cells (ENST00000381886).
This ERβ-specific isoform is missing the N-terminal 84
amino acids, a region of the protein of critical importance
for interaction with substrates. This suggests the possibil-
ity of a switch in substrate affinity induced by ERβ. This is
particularly interesting as USP7 is a deubiquitinating en-
zyme, responsible for removing ubiquitin chains from
both the tumor suppressor p53 and its negative regulator
Mdm2 [51], which instead is an ubiquitin ligase inducing
degradation of p53. As USP7 binds both p53 and Mdm2
with the same N-terminal domain [51], the overall effect
of its enzymatic activity is highly dependent on the relative
affinity for the two targets. The ERβ-induced switch may
alter this equilibrium, thus modulating such a relevant
aspect of cancer biology as p53 stability. In the case of
IFNγ Receptor 2, ERα induced expression of the full
length transcript (ENST00000381995), while ERβ favored
a switch toward truncated forms (ENST00000545369,
ENST00000405436) lacking the transmembrane domain,
and therefore predicted to be secreted as soluble forms in
the extracellular environment, with the potential of acting
as dominant negative modulators of interferon signaling.
In another example (the gene PSEN1, involved in intra-
membrane proteolysis and cleavage of the intracellular
domain of transmembrane proteins such as amyloid
precursor protein and Notch and therefore a potential
therapeutic target in BC [52]), the ERβ-induced splicing
switch did not alter the open reading frame but caused
the expression of a longer mRNA (ENST00000366783)
compared to the isoform that was favored by ERα
(ENST00000422240), possibly affecting the rate of transla-
tion or stability of the mRNA.
Another way of finding hints to the biological conse-
quences of ERβ-specific splicing events described here is
the reconstruction of pathways whose genes are differen-
tially spliced following ERβ introduction in the cells. For
instance, we found many genes involved in the Notch sig-
naling pathway differentially spliced by ERβ: the above-
mentioned PSEN2 is the catalytic subunit of the γ-secretase
complex, responsible for intramembrane proteolysis of
transmembrane receptors including Notch, resulting in
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migrates to the nucleus and regulates transcription of tar-
get genes [53]. Also, NCOR2 is bound to the unliganded
CBF-1 transcription factor, a primary effector of Notch
signaling which acts as a repressor in unstimulated cells,
but is converted to an activator (dismissing the corepres-
sor NCOR2) after binding the NICD [54]. Furthermore,
POGLUT1 has recently been shown to be an endoplasmic
reticulum O-glycosyl-transferase responsible for glycosy-
lation of Notch and required for its function [55], and
SLC35C2 is an endoplasmic reticulum transporter respon-
sible for accumulation of GDP-fucose, which is used for
Notch fucosylation, required for full activation [56]. Fi-
nally, SGK1 has recently been shown to be a negative
regulator of Notch signaling by inhibiting γ-secretase ac-
tivity and promoting Notch degradation [57], and MAGI1
has been shown to recruit Notch ligand Dll1 to cadherin-
based adherens junctions, stabilizing it on the cell surface
[58]. It is worth noting that the predominant Notch recep-
tor expressed in these cell lines was Notch2, which was
induced by E2 in wt cells (to a level slightly below the
chosen cut-off threshold, but highly statistically signifi-
cant: FPKM without E2: 49.826; FPKM with E2: 61.583,
FC 1.236, q-value 0.0005), while its basal expression
was lowered and its up-regulation smoothened in the
ERβ + cells.
A possible modulation of the Notch pathway by ERβ is
especially interesting as Notch is a known regulator of
breast development and maintenance of breast stem
cells [59]; alterations in the Notch pathway have been in-
volved in breast carcinogenesis, and in particular the
Notch pathway has been implicated in the development
of triple negative BC (TNBC), a particularly aggressive
form of BC which does not express ERα, progesterone
receptor (PR) or HER2, and which has shown resistance
to all known therapies [60]. Targeting Notch signaling
has been proposed in TNBC. As these cancers are ERα-
negative, hormonal treatment is not currently used for
these patients; however, ERβ could be expressed in up to
50% of TNBCs [10,18], and its expression in TNBC has
been associated with better prognosis [18]. Therefore,
ERβ may represent a potential new therapeutic target in
TNBC. The interrelation between ERβ and Notch in the
development and prognosis of triple-negative BC should
be investigated further in future research.
Conclusions
In conclusion, whole-genome analysis of early transcrip-
tion evens and mRNA processing associated with ERβ
confirmed a relevant role for this receptor in modulating
ERα-dependent transcription and splicing, but also
identified novel, ERβ-specific transcription and splicing
events, confirming a wide range of actions of ERβ in the
biology of BC.The data reported here confirm the complexity of
estrogen action in BC cells and provide a comprehensive
description of the effects of ERα and by ERβ on early tran-
scription and splicing in hormone-responsive BC cells.
More importantly, they provide a starting point to identify
the events of ERβ-dependent splicing which are most
significant for cancer biology.Methods
Human hormone-responsive BC cells
Stable cell clones expressing either C-TAP-ERβ or N-TAP-
ERβ (ERβ+) generated as previously described [23], and
wild type (wt) MCF7 (ERβ-) cells were used for this
study. All cell lines were maintained, propagated, hormone-
starved for 5 days and analyzed for estrogen signaling as
described earlier [21,45].Illumina RNA sequencing library preparation
Total RNA was extracted from hormone-starved cell
cultures (+Ethanol -E2) or after 2 hours of stimulation
with 10-8 M 17β-estradiol (+E2), as described previously
[21]. RNA concentration in each sample was deter-
mined with a NanoDrop-1000 spectrophotometer and
the quality assessed with the Agilent 2100 Bioanalyzer
and Agilent RNA 6000nano cartridges (Agilent Technolo-
gies). Indexed libraries were prepared from 1 μg/ea. of puri-
fied RNA with TruSeq Stranded total RNA Sample Prep
Kit (Illumina) according to the manufacturer’s instructions.
Libraries were sequenced (paired-end, 2×100 cycles) at a
concentration of 8 pmol/L per lane on HiSeq1500 platform
(Illumina) with a coverage of >70 million sequence reads/
sample on average.Read alignment and transcript assembly
TopHat v.2.0.10 [61] was used to align all reads includ-
ing junction-spanning reads back to the human genome
(Homo sapiens Ensembl GRCh37, hg19). To identify the
differentially expressed and spliced genes and isoforms
between ERβ- and ERβ + cell lines we used Cuffdiff
v2.1.1 [44]. The parameters to define genes and isoforms
as differentially expressed were the following: expression
level threshold of 0.5 FPKM; q-value (FDR-adjusted p-
value of the test statistic) ≤ 0.05 and |FC| ≥ 1.3. Moreover,
to detect the ERβ- and ERβ + BC-specific splice events
such as exon skip, exon inclusion, alternative splice sites
and intron retention, we performed a direct comparison
analysis using MATS v3.0.8 [37]. To filter events with at
least 10% change in exon inclusion level we set the MATS
cutoff c, representing the extent of splicing change one
wishes to identify, to 0.1, and FDR ≤ 0.05 to filter the iden-
tified splice events.
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RNA-Seq data have been deposited in the Gene Expression
Omnibus genomics data public repository (http://www.
ncbi.nlm.nih.gov/geo/) with Accession Number GSE64590.
Additional files
Additional file 1: Figure S1. Description: KEGG pathway (Kanehisa et al.
Nucleic Acids Res 2014, 42:D199) analysis of ERα and ERβ interactors
involved in Spliceosome Pathway. Blue and red boxes highlight ERα and
ERβ interacting proteins, respectively.
Additional file 2: Tables S1. A: Ct-ERβ gene list. Genes with a FPKM
value ≥0.5, q-value ≤0.05 and |FC|≥ 1.3 in the Ct-ERβ BC cell line. B:
Nt-ERβ gene list. Genes with a FPKM value ≥0.5, q-value ≤0.05 and
|FC| ≥1.3 in the Nt-ERβ BC cell line. C: MCF-7 wt gene list. Genes with a
FPKM value ≥0.5, q-value ≤0.05 and |FC| ≥1.3 in the wt MCF-7 BC cell
line. D: Commonly regulated genes in both ERβ + BC cell lines. Genes
consistently regulated in both ERβ + BC cells with a q-value ≤0.05 and
|FC| ≥1.3. E: Ct-ERβ isoform list. Isoforms with a FPKM value ≥0.5, q-value
≤0.05 and |FC| ≥1.3 in the Ct-ERβ BC cell line. F: Nt-ERβ isoform list.
Isoforms with a FPKM value ≥0.5, q-value ≤0.05 and |FC| ≥1.3 in the
Nt-ERβ BC cell line. G: MCF-7 wt isoform list. Isoforms with a FPKM
value ≥0.5, FDR ≤0.05 and |FC| ≥1.3 in the wt MCF-7 BC cell line.
Additional file 3: Tables S2. A: List of exon skipping events in Ct-ERβ, B:
List of mutually exclusive exons in Ct-ERβ, C: List of retained introns in Ct-ERβ,
D: List of alternative 3’ splice sites in Ct-ERβ, E: List of alternative 5’ splice sites
in Ct-ERβ, F: List of exon skipping events in Nt-ERβ, G: List of mutually
exclusive exons in Nt-ERβ, H: List of retained introns in Nt-ERβ, I: List of
alternative 3’ splice sites in Nt-ERβ, J: List of alternative 5’ splice sites in Nt-ERβ,
K: List of exon skipping events in wt MCF-7, L. List of mutually exclusive exons
in wt MCF-7, M: List of retained introns in wt MCF-7, N. List of alternative 3’
splice sites in wt MCF-7, O: List of alternative 5’ splice sites in wt MCF-7.
Additional file 4: Table S3. Discordant Isoforms ERβ+/ERβ-. List of all
isoforms with opposite regulation pattern in ERβ+/ERβ-.
Additional file 5: Tables S4. A: Differential Promoter Usage Ct-ERβ. Gene
list with differential promoter usage (DPU) in the Ct-ERβ BC cell line (FDR
≤0.05). B: Differential Promoter Usage Nt-ERβ. Gene list with DPU in the Nt-
ERβ BC cell line (FDR ≤0.05). C: Differential Promoter Usage MCF-7 wt. Gene list
with DPU in the wt MCF-7 BC cell line (FDR ≤0.05). D: Differential Spliced Gene
Ct-ERβ. Gene list differentially spliced (DSGs) in the Ct-ERβ BC cell line (FDR
≤0.05). E: Differential Spliced Gene Nt-ERβ. Gene list differentially spliced (DSGs)
in the Nt-ERβ BC cell line (FDR ≤0.05). F: Differential Spliced Gene MCF-7 wt.
Gene list differentially spliced (DSGs) in the wt MCF-7 BC cell line (FDR ≤0.05).
Additional file 6: Table S5. PSD3 TSSs expression values. Transcript
starting sites (TSSs) expression value list of the PSD3 gene, expressed in FPKM
with relative FC, FDR and p-value in Ct-ERβ, Nt-ERβ and MCF-7 wt BC cell lines.
Additional file 7: Tables S6. A: ERα binding sites in Ct-ERβ. Gene list of
DSGs including ERα binding sites in a 10 kb window around the gene in
the Ct-ERβ BC cell line. B: ERβ binding sites in Ct-ERβ. Gene list of DSGs
including ERβ binding sites in a 10 kb window around the gene in the
Ct-ERβ BC cell line. C: ERα binding sites in Nt-ERβ. Gene list of DSGs including
ERα binding sites in a 10 kb window around the gene in the Nt-ERβ BC cell
line. D: ERβ binding sites in Nt-ERβ. Gene list of DSGs including ERβ binding
sites in a 10 kb window around the gene in the Nt-ERβ BC cell line. E: ERα
binding sites in MCF-7 wt. Gene list of DSGs including ERα binding sites in a
10 kb window around the gene in the wt MCF-7 BC cell line.
Additional file 8: Figure S2. Heat map representing the clustered density
matrix of ERα and ERβ binding sites. Chromatin immunoprecipitation of ERα
and ERβ in Ct-ERβ and wt MCF-7 cells show different ER binding profiles
(highlighted by square brackets). In the clustering, each line represents a
genomic location of a binding site with its surrounding ±1.5 kb region. This
matrix was subjected to k-means clustering.
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